AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.

Phase 3

Active, not recruiting

Conditions: Stage IB-IIIA Non-small Cell Lung Carcinoma

Interventions: Drug: AZD9291 80 mg/40 mg
Drug: Placebo AZD9291 80 mg/40 mg
Drug: Open-label AZD9291 80 mg/40 mg

Registration Number: NCT02511106

Lead Sponsor: AstraZeneca

Brief Summary: To assess the efficacy and safety of AZD9291 versus Placebo, in patients with Epidermal Growth Factor Receptor Mutation Positive stage IB-IIIA non-small cell lung carcinoma, following complete tumour resection with or without adjuvant chemotherapy

Detailed Description: This is a phase 3 double-blind, randomized, placebo-controlled, study to assess the efficacy and safety of AZD9291 versus placebo in patients with stage IB-IIIA non-small cell lung cancer (NSCLC) with centrally confirmed, most common sensitising EGFR mutations (Ex19Del and L858R) either alone or in combination with other EGFR mutations as confirmed by a central test, who have had complete tumour resection, with or without postoperative adjuvant chemotherapy. Adjuvant chemotherapy should have consisted of a platinum based doublet given for a maximum of 4 cycles.

Recruitment & Eligibility

Status: ACTIVE_NOT_RECRUITING

Sex: All

Target Recruitment: 682

Inclusion Criteria

Male or female, aged at least 18 years.
Histologically confirmed diagnosis of primary non small lung cancer (NSCLC) on predominantly non-squamous histology
MRI or CT scan of the brain must be done prior to surgery as it is considered standard of care.
Patients must be classified post-operatively as Stage IB, II or IIIA on the basis of pathologic criteria.
Confirmation by the central laboratory that the tumour harbours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR mutations including T790M.
Complete surgical resection of the primary NSCLC is mandatory. All gross disease must have been removed at the end of surgery. All surgical margins of resection must be negative for tumour.
Complete recovery from surgery and standard post-operative therapy (if applicable) at the time of randomization.
World Health Organization Performance Status of 0 to 1.
Female patients should be using adequate contraceptive measures, should not be breast feeding, and must have a negative pregnancy test prior to first dose of study drug; or female patients must have an evidence of non-child-bearing potential.

Exclusion Criteria

Treatment with any of the following:
- Pre-operative or post-operative or planned radiation therapy for the current lung cancer
- Pre-operative (neo-adjuvant) platinum based or other chemotherapy
- Any prior anticancer therapy
- Prior treatment with neoadjuvant or adjuvant EGFR-TKI at any time
- Major surgery (including primary tumour surgery, excluding placement of vascular access) within 4 weeks of the first dose of study drug
- Patients currently receiving medications or herbal supplements known to be potent inducers of cytochrome P450 (CYP) 3A4
- Treatment with an investigational drug within five half-lives of the compound or any of its related material.
Patients who have had only segmentectomies or wedge resections
History of other malignancies, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer, or other solid tumours curatively treated with no evidence of disease for > 5 years following the end of treatment.
Any unresolved toxicities from prior therapy greater than CTCAE Grade 1 at the time of starting study treatment with the exception of alopecia and Grade 2, prior platinum-therapy related neuropathy.
Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses; or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV).
Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of AZD9291.
Any of the following cardiac criteria:
- Mean resting corrected QT interval (QTc) >470 msec, obtained from 3 ECGs, using the screening clinic ECG machine-derived QTc value.
- Any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG.
- Any factors that increase the risk of QTc prolongation or risk of arrhythmic events, or unexplained sudden death under 40 years of age in first-degree relatives or any concomitant medication known to prolong the QT interval.
Past medical history of ILD, drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active ILD.
Inadequate bone marrow reserve or organ function.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
AZD9291	AZD9291 80 mg/40 mg	AZD9291 (80 mg or 40 mg orally, once daily), in accordance with the randomization schedule.
Placebo AZD9291	Placebo AZD9291 80 mg/40 mg	Matching placebo for AZD9291 (80 mg or 40 mg orally, once daily), in accordance with the randomization schedule.
AZD9291	Open-label AZD9291 80 mg/40 mg	AZD9291 (80 mg or 40 mg orally, once daily), in accordance with the randomization schedule.

Primary Outcome Measures

Name	Time	Method
Assess the Efficacy of AZD9291 Compared to Placebo as Measured by Disease Free Survival (DFS).	Up to approximately 5 years after the first patient is randomized (maximum follow up of 70 months)	Defined as the time from the date of randomization until the date of disease recurrence or death (by any cause in the absence of recurrence).

Secondary Outcome Measures

Name	Time	Method
Disease Free Survival (DFS) Rate at 2, 3 and 5 Years	Up to approximately 5 years after the first patient is randomized (maximum follow up of 70 months). DFS rate at 2 years (%), 3 years (%) and 5 years (%) are presented.	Defined as the percentage of patients alive and disease free at 2, 3 and 5 years, respectively, estimated from Kaplan Meier plots of the primary endpoint of DFS.
Overall Survival Rate at 2, 3 and 5 Years	Up to approximately 7 years after the first patient is randomized (maximum follow up of 86 months). OS rate at 2 years (%), 3 years (%) and 5 years (%) are presented.	Defined as the percentage of patients alive at 2, 3 and 5 years, respectively, estimated from a Kaplan Meier plot of OS.
Plasma Concentrations of AZD9291	Collected at pre-dose, 0.5-1.5hours and 2-4hours post-dose up to 96 weeks (approximately 24 months)	The pharmacokinetics exposure parameters derived from plasma concentrations of AZD9291
Overall Survival (OS)	Up to approximately 7 years after the first patient is randomized (maximum follow up of 86 months)	Defined as the time from the date of randomization until date of death due to any cause.
Patient Health-related Quality of Life and Symptoms (HRQoL) by SF-36v2 Health Survey.	Measured by SF-36 Questionnaire at baseline, 12 week, 24 week and then every 24 weeks until study complete, disease recurrence or other discontinuation criteria met, up to 3 years.	Change from baseline will be calculated for each domain and summary scale at each scheduled post-baseline assessment. The SF-36 includes eight domains: Physical Functioning (PF); Role Limitations-Physical (RP), Vitality (VT), General Health Perceptions (GH), Bodily Pain (BP), Social Function (SF), Role Limitations-Emotional (RE), and Mental Health (MH) and two summary scores: The Physical Component Summary (PCS) and Mental Component Summary (MCS). Final scores for each scale range from 0-100 with higher scores indicating better health.
Plasma Concentrations of AZ5104 Metabolites	From date of dosing to week 96 (approximately 24 months)	The pharmacokinetics exposure parameters derived from plasma concentrations of AZ5104 metabolites
Plasma Concentrations of AZ7550 Metabolites	From date of dosing to week 96 (approximately 24 months)	The pharmacokinetics exposure parameters derived from plasma concentrations of AZ7550 metabolites